Myeloproliferative Neoplasms (MPNs)
Ruben Mesa, MD
One of the top myeloproliferative neoplasms or MPN specialists in the U.S., Dr. Ruben Mesa, shares his thoughts on the latest in research on MPNs treatments, including drugs and combinations that produce promising results throughout clinical trials and research.
Dr. Mesa’s Interviews
Ruben Mesa, MD
- Executive Director, Mays Cancer Center at UT Health San Antonio MD Anderson
- Mays Family Foundation Distinguished University Presidential Chair
- Professor of Medicine
What drew you to medicine and to myeloproliferative neoplasms?
Dr. Ruben Mesa: When I was back as a medical student at Mayo Medical School in Rochester, Minnesota, back now 30 years ago, this very fall. As a first-year medical student, one of the first patients I saw as a medical student while working alongside someone whom I was rotating with was a patient with myelofibrosis.
So that individual still in their fellowship at that time, a very famous MPN specialist by the name of Dr. Jafari, I had a chance to visit with this woman. She was young, from South America, and she really had a very difficult case of myelofibrosis.
It gave me a chance to learn more about the disease, the difficulties that patients faced and got involved with research both with Dr. Jafari and other colleagues realize the tremendous opportunities. We had to develop better treatments. And the rest is history.